Sector News

Vaccitech appoints new chief medical officer

August 7, 2019
Life sciences

Vaccitech, a clinical-stage T cell immunotherapy company developing viral vectors as vaccines to treat and prevent cancer and infectious diseases, announces today that it has appointed Mariem Charafeddine as its new chief medical officer.

Mariem brings over 15 years’ experience in the biopharmaceutical industry, spent both advancing the clinical development and commercialisation of infectious disease products, and in delivering post-marketing monitoring of licensed medical products. She has also previously worked in international medical leadership roles and drug development in infectious diseases.

“We are delighted to have Mariem join our team as we advance towards the Phase IIb read-outs of our lead clinical program in influenza,” said Tom Evans, Vaccitech CEO.

He continued, “Her wide-ranging clinical development and post-marketing expertise in infectious diseases also puts us in great stead ahead of first in human studies for our HPV and HBV therapeutics. We look forward to her input on how best to develop our vaccines for the patients that need them.”

By: Anna Smith

Source: Pharma Times

2 responses to “Vaccitech appoints new chief medical officer

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend